JW THERAP-B

JW Cayman Therapeutics opened at HKD 1.790 and climbed to HKD 1.885 in the morning session, a 5.3% gain, driven by its upcoming board meeting to review interim results and recent regulatory acceptance of the supplemental application for Carteyva® using a domestic lentiviral vector. Despite revenue surging 159.56% YoY to HKD 98.59 million, EPS loss remained at HKD -0.385 and net profit margin was -162.4%. The stock trades 70.3% below its 52-week high of HKD 6.35 but 34.6% above the low of HKD 1.4, and sits above both the MA20 (1.727) and MA60 (1.744).

JW Cayman Therapeutics opened higher and continued to rally, gaining 5.7% in the morning session, driven by the announcement of a board meeting to review interim results and expectations that its CAR-T product Carteyva could be included in commercial insurance catalogs. The company recently submitted Phase I data for Carteyva in systemic lupus erythematosus, boosting market sentiment. While Q4 revenue surged 159.56% YoY to HK$98.6 million, net loss remained at HK$160.1 million, with a net profit margin of -162.4% and ROE of -103.6%, indicating persistent fundamental pressure. The stock closed at HK$1.935, 69.5% below its 52-week high of HK$6.35, but has recovered above both the 20-day (HK$1.704) and 60-day (HK$1.754) moving averages, though YTD it remains down 22.6%.

JW Therapeutics opened higher and climbed steadily in the morning session, reaching HKD 1.97 as of 10:22 BJ, up 5.35% from the previous close, with the intraday high of HKD 1.97 and low of HKD 1.87 forming a single-session uptrend. The rally was driven by persistent expectations of its CAR-T product Carteyva® being included in the commercial insurance catalog, alongside optimism following management changes where CEO Feng Tian assumed the chairman role after Cheng Liu's retirement. Q4 2025 revenue surged 159.56% YoY to HKD 98.6 million, while net loss narrowed 14.07% YoY, though net profit margin remained deeply negative at -162.45%. The stock is still 68.98% below its 52-week high of HKD 6.35 but has recovered above both the 20-day (HKD 1.684) and 60-day (HKD 1.771) moving averages, while YTD it remains down 21.2%. However, the PB of 1.33x and negative PE suggest limited fundamental support.

JW Cayman Therapeutics surged in Monday's morning session, hitting an intraday high of HKD 1.945 before closing at HKD 1.900, up 6.1%, driven by positive news flow and earnings. The company's Phase I clinical data for its CAR-T therapy, Carteyva®, in systemic lupus erythematosus was accepted by the NMPA, and reports suggest the drug may enter the commercial insurance catalog, reigniting optimism on its commercial prospects. Q4 revenue surged 159.56% YoY to HKD 98.6 million, but net loss remained at HKD 160 million, with a net margin of -162.4%, indicating profitability is still distant. The stock at HKD 1.9 has rebounded 35.7% from its 52-week low of HKD 1.4, yet remains 70% below its 52-week high of HKD 6.35 and is down 24% YTD, still below its 60-day MA of HKD 1.778, reflecting a bearish technical posture. However, the company recently underwent significant leadership changes, with CEO Feng Tian replacing Cheng Liu as chairman, introducing uncertainty about the new team's strategy.

JW Therapeutics opened higher and rallied in the morning session, reaching HKD 1.660 by 9:55 BJ time, up 5.40% from the previous close of HKD 1.575. The surge was driven by a series of positive developments: its CAR-T product Carteyva® advanced in commercial insurance inclusion with expert review passing five CAR-T drugs, and the company's domestic viral vector supplementary application was accepted by the NMPA. Additionally, the disclosure of a new CD19/20 dual-target CAR-T pipeline and strong Q4 revenue growth of 159.56% YoY to HKD 98.6 million, alongside a 14.07% YoY narrowing of net loss, reinforced improving fundamentals. However, the stock remains 74.22% below its 52-week high of HKD 6.44 and below the MA60 of HKD 1.784, with a YTD decline of 33.6%, suggesting the rally's sustainability is uncertain.